Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
OPKO Health Inc
OPK
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.66
0.05
3.11%
Dern. MÀJ: Oct 20, 5:59 PM
$1.65
0.0429
2.66%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Fusions et acquisitions:
OPKO Health (OPK) announced it will sell assets to Labcorp Holdings (LH) on Thursday, October 15, 2026 for $722M paid in cash
OPKO Health Financials
OPKO Health (OPK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Crude Oil Moves Higher; Charles Schwab Shares Fall After Q3 Results
U.S. stocks mixed: Dow gained 450+ points, S&P rose, Nasdaq slipped. Healthcare led gains; energy fell. Oil and gold climbed, Asian markets mostly
Avi Kapoor
PRO
OPKO Health Raises FY2026 Sales Guidance from $530.000M-$560.000M to $560.000M-$585.000M vs $534.899M Est
OPKO Health (NASDAQ:OPK) raises FY2026 sales outlook from $530.000 million-$560.000 million to $560.000 million-$585.000 million vs $534.899 million estimate.
Benzinga Newsdesk
PRO
OPKO Health Sees Q3 Sales $131.000M-$142.000M vs $134.650M Est
OPKO Health (NASDAQ:OPK) sees Q3 sales of $131.000 million-$142.000 million vs $134.650 million analyst estimate.
Benzinga Newsdesk
PRO
OPKO Health Q2 EPS $(0.01), Sales $163.500M Beat $131.233M Estimate
OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.5 percent. This is a 85.71 percent increase over losses of $(0.07) per share from the
Benzinga Newsdesk
PRO
OPKO Health Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $551.214M Est
OPKO Health (NASDAQ:OPK) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $551.214 million estimate.
Benzinga Newsdesk
PRO
OPKO Health Sees Q2 Sales $127.000M-$132.000M vs $136.329M Est
OPKO Health (NASDAQ:OPK) sees Q2 sales of $127.000 million-$132.000 million vs $136.329 million analyst estimate.
Benzinga Newsdesk
